Search Results - "Alloo, Allireza"

Refine Results
  1. 1

    Incidence of hidradenitis suppurativa in the United States: A sex- and age-adjusted population analysis by Garg, Amit, MD, Lavian, Jonathan, BA, Lin, Gloria, MS, Strunk, Andrew, MA, Alloo, Allireza, MD

    “…Background The true incidence of hidradenitis suppurativa (HS) is unknown. Objective To determine standardized incidence estimates for HS in the United States…”
    Get full text
    Journal Article
  2. 2

    Interstitial granulomatous dermatitis and granulomatous arteritis in the setting of PD‐1 inhibitor therapy for metastatic melanoma by Singh, Parmvir, Wolfe, Scott P., Alloo, Allireza, Gottesman, Silvija P.

    Published in Journal of cutaneous pathology (01-01-2020)
    “…Checkpoint inhibition has become an important target in the management of malignant melanoma. As anti‐CTLA4 inhibitors and anti‐PD1 antibodies are increasingly…”
    Get full text
    Journal Article
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7

    A 25-Year-Old Male with Orogenital Ulcers, Rash, and Difficulty Swallowing by Ko, Lauren N., Alloo, Allireza, Lin, William M., Hoang, Mai P., Kroshinsky, Daniela

    Published in Dermatopathology (Basel, Switzerland) (08-11-2017)
    “…A 25-year-old otherwise healthy male presented with new-onset odynophagia, rash, and orogenital ulcers. Despite treatment with antibiotics for presumed…”
    Get full text
    Journal Article
  8. 8

    Prevalence estimates for pyoderma gangrenosum in the United States: An age- and sex-adjusted population analysis by Xu, Amy, Balgobind, Amrita, Strunk, Andrew, Garg, Amit, Alloo, Allireza

    “…The disease burden of pyoderma gangrenosum (PG) is poorly understood. To determine standardized overall and age-, sex-, and race-specific prevalence estimates…”
    Get full text
    Journal Article
  9. 9

    Real-world risk of new-onset inflammatory bowel disease among patients with psoriasis exposed to interleukin 17 inhibitors by Wright, Shari, Alloo, Allireza, Strunk, Andrew, Garg, Amit

    “…Information on the real-world risk of inflammatory bowel disease (IBD) among patients with psoriasis exposed to interleukin-17 inhibitor (IL-17i) is limited…”
    Get full text
    Journal Article
  10. 10
  11. 11

    Prevalence estimates for pemphigoid in the United States: A sex-adjusted and age-adjusted population analysis by Wertenteil, Sara, Garg, Amit, Strunk, Andrew, Alloo, Allireza

    “…The burden of the pemphigoid group of autoimmune blistering diseases is poorly understood. To estimate standardized overall and sex-specific, age-specific, and…”
    Get full text
    Journal Article
  12. 12

    Validation of a Case-Finding Algorithm for Hidradenitis Suppurativa Using Administrative Coding from a Clinical Database by Strunk, Andrew, Midura, Margaretta, Papagermanos, Vassiliki, Alloo, Allireza, Garg, Amit

    Published in Dermatology (Basel) (01-01-2017)
    “…Requisite to the application of clinical databases for observational research in hidradenitis suppurativa (HS) is the identification of an accurate case…”
    Get more information
    Journal Article
  13. 13
  14. 14

    Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma by Alloo, Allireza, Garibyan, Lilit, LeBoeuf, Nicole, Lin, George, Werchniak, Andrew, Hodi, Jr, F Stephen, Flaherty, Keith T, Lawrence, Donald P, Lin, Jennifer Y

    Published in Archives of dermatology (1960) (01-03-2012)
    “…The development of keratoacanthomas (KAs) and well-differentiated squamous cell carcinomas (SCCs) is a known adverse effect of novel BRAF inhibitors such as…”
    Get more information
    Journal Article
  15. 15

    Cutaneous immune-related adverse events to checkpoint inhibitors by Malviya, Neeta, Tattersall, Ian W., Leventhal, Jonathan, Alloo, Allireza

    Published in Clinics in dermatology (01-11-2020)
    “…The development of immunotherapy has led to a paradigm shift in the treatment of both solid and hematologic malignancies. As immunomodulatory therapies are…”
    Get full text
    Journal Article
  16. 16

    Outcome Measurement Instruments Used to Evaluate Dermatologic Adverse Events in Cancer Trials: A Systematic Review by Shaigany, Sheila, Mastacouris, Nicole, Tannenbaum, Rachel, Strunk, Andrew, Luan, Christopher, Burshtein, Joshua, Burshtein, Aaron, Carvajal, Richard, Garg, Amit, Alloo, Allireza

    Published in JAMA dermatology (Chicago, Ill.) (01-06-2024)
    “…Assessment of type, severity, and impact of dermatologic adverse events (DAEs) necessitates well-developed and validated clinician-reported outcome measures…”
    Get more information
    Journal Article
  17. 17
  18. 18
  19. 19
  20. 20